Galectin-3 (gal-3), a galactoside-binding lectin, is a promising new cardiac biomarker, which was included in the 2013 heart failure management guide and confirmed to have the function of detecting the risk of adverse events (Yancy et al., 2013). This evidence concerns the gene LGALS3 and heart failure.